1. Halper Sadeh LLC investigates INZY's sale to BioMarin at $4.00/share. 2. Concerns over fairness and fiduciary duties of INZY's board are raised. 3. Shareholders could seek increased consideration or additional disclosures. 4. Securities laws may have been violated in the sale process.
The investigation may indicate potential under-valuation and legal risks impacting stock sentiment, similar to past cases where shareholder lawsuits led to decreased market confidence.
The investigation directly challenges the terms of INZY's proposed acquisition, which could yield significant financial implications for shareholders.
Immediate uncertainty around the transaction could affect stock price swiftly, as investors react to potential legal implications.
NEW YORK--(BUSINESS WIRE)-- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inozyme Pharma, Inc. (NASDAQ: INZY) to BioMarin Pharmaceutical Inc. for $4.00 per share is fair to Inozyme shareholders.
Halper Sadeh encourages Inozyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
The investigation concerns whether Inozyme and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Inozyme shareholders; (2) determine whether BioMarin is underpaying for Inozyme; and (3) disclose all material information necessary for Inozyme shareholders to adequately assess and value the merger consideration.
On behalf of Inozyme shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.